Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Sanofi 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Sanofi 3Q

Product sales up for the first time in five quarters

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi

3Q Revenues: €8.4 billion (-7%)

3Q Earnings: €1.8 billion (-19%)

YTD Revenues: €24.5 billion (-7%)

YTD Earnings: €4.9 billion (-26%)

Comments: Pharmaceutical sales were €6.7 million in the quarter, up 3%.Sales lost to generic competition on key legacy products in the U.S. and EU were €191 million. Diabetes sales were up 20% to €1.7 million with Lantus sales of €1.5 million (+21%). Vaccines sales were €1.3 billion (-7%) impacted by supply limitations of Pentaceland Adacel in the U.S. and the quarterly phasing of U.S. flu vaccines sales. Genzyme sales grew 21% to €529 million driven by the 11% growth of the rare disease franchise and the launch of Aubagio. Emerging Markets sales were €2.7 billion, up 3% and were impacted by lower growth in the Chinese pharmaceutical market and lower sales of Brazil generics. Consumer Healthcare grew 10% reflecting the launch of Rolaids in the U.S. and the improvement of the CHC business in China. Animal Health sales were €458 million, down 6% due to increased competition to Frontline.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters